A phase 1 open-label pilot study of low-dose interleukine-2 immunotherapy in patients with Alzheimer's disease.
Faridar A, Eid AM, Thome AD, Zhao W, Beers DR, Pascual MB, Nakawah MO, Roman GC, Davis CS, Grundman M, Masdeu JC, Appel SH.
Faridar A, et al. Among authors: eid am.
Transl Neurodegener. 2023 Nov 16;12(1):54. doi: 10.1186/s40035-023-00387-5.
Transl Neurodegener. 2023.
PMID: 37968718
Free PMC article.
Clinical Trial.